{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:27:07Z","timestamp":1787923627594,"version":"build-2784847793"},"reference-count":118,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tumor necrosis factor-like ligand 1A (TL1A), encoded by TNFSF15, signals through death receptor 3 on effector T cells, innate lymphoid cells, and intestinal myofibroblasts, driving both chronic intestinal inflammation and tissue fibrosis. In this narrative review, we provide a contemporary appraisal of TL1A-directed therapeutics in inflammatory bowel disease based on electronic searches through May 2026. Three anti-TL1A monoclonal antibodies (tulisokibart, afimkibart, and duvakitug) have advanced to phase 3 trials across multiple global programs, with phase 2 clinical remission rates of 26%-48% in ulcerative colitis (placebo-adjusted differences 15-26 percentage points) and endoscopic response rates of 26%-48% in Crohn\u2019s disease, alongside favorable safety profiles. Mucosal transcriptomic and serum proteomic analyses from phase 2 trials, including DDW 2026 readouts from ARTEMIS-UC and TUSCANY-2, provide the first human-tissue confirmation of class antifibrotic activity through the suppression of Th17, myeloid, and extracellular matrix pathways. TNFSF15 risk-variant companion diagnostics are advancing, although their incremental utility remains modest and will be definitively tested in phase 3. The pipeline has expanded to at least 19 development programs, including extended half-life antibodies (XmAb942, SPY002, and BCD-261), bispecifics combining TL1A with IL-23 or \u03b14\u03b27 (RO7837195, XmAb412, LQ080, and ALX001), a first-in-class oral anti-TL1A nanobody, and a first-in-class DR3 receptor antagonist (SL-325). We discuss therapeutic positioning and timing, the opportunity in acute severe UC, and the unusual standing of IBD as the lead indication for this mechanism class. Phase 3 results anticipated in 2026-2027 will be particularly informative for fibrostenotic phenotypes and biologic-refractory patients.<\/jats:p>","DOI":"10.1093\/ibd\/izag172","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:41:28Z","timestamp":1785843688000},"source":"Crossref","is-referenced-by-count":0,"title":["Targeting the TL1A pathway in inflammatory bowel disease: mechanistic insights and emerging therapeutic pipeline"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1673-7792","authenticated-orcid":false,"given":"Mohammed Nabil","family":"Quraishi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City , Abu Dhabi,","place":["United Arab Emirates"]},{"name":"Institute of Cancer and Genomic Sciences, University of Birmingham , Birmingham,","place":["United Kingdom"]},{"name":"College of Medicine and Health Sciences, Khalifa University of Science and Technology , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0033","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Western University , London, Ontario,","place":["Canada"]},{"name":"Alimentiv, Inc , London, Ontario,","place":["Canada"]},{"name":"London Health Research Institute , London, Ontario,","place":["Canada"]},{"name":"Department of Epidemiology and Biostatistics, University of Western Ontario , London, Ontario,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6102-9267","authenticated-orcid":false,"given":"Badr","family":"Al-Bawardy","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, King Faisal Specialist Hospital and Research Center , Riyadh,","place":["Saudi Arabia"]},{"name":"Department of Internal Medicine, Section of Digestive Diseases, Yale School of Medicine , New Haven, CT,","place":["United States"]},{"name":"College of Medicine, Alfaisal University , Riyadh,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"2026082801031934500_izag172-B1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs","year":"2025","journal-title":"Nature"},{"key":"2026082801031934500_izag172-B2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026082801031934500_izag172-B3","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","article-title":"Breaking through the therapeutic ceiling: what will it take?","volume":"162","author":"Raine","year":"2022","journal-title":"Gastroenterology"},{"key":"2026082801031934500_izag172-B4","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cgh.2024.06.050","article-title":"Modern advanced therapies for inflammatory bowel diseases: practical considerations and positioning","volume":"23","author":"Fudman","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026082801031934500_izag172-B5","doi-asserted-by":"publisher","first-page":"101981","DOI":"10.1016\/j.bpg.2025.101981","article-title":"Reaching the therapeutic ceiling in IBD: can advanced combination treatment (ACT) offer a solution?","volume":"77","author":"Solitano","year":"2025","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2026082801031934500_izag172-B6","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/gutjnl-2023-329963","article-title":"Fibrosis in IBD: from pathogenesis to therapeutic targets","volume":"73","author":"Rieder","year":"2024","journal-title":"Gut"},{"key":"2026082801031934500_izag172-B7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S2468-1253(25)00263-8","article-title":"Ulcerative colitis: moving beyond the mucosal dogma","volume":"11","author":"Eggermont","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026082801031934500_izag172-B8","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/apt.14526","article-title":"Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation","volume":"47","author":"Gordon","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026082801031934500_izag172-B9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ibd\/izab251","article-title":"Immunological regulation of intestinal fibrosis in inflammatory bowel disease","volume":"28","author":"Bamias","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026082801031934500_izag172-B10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.medj.2024.03.010","article-title":"TL1A inhibition for inflammatory bowel disease treatment: from inflammation to fibrosis","volume":"5","author":"Solitano","year":"2024","journal-title":"Med"},{"key":"2026082801031934500_izag172-B11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S1074-7613(02)00283-2","article-title":"TL1A is a TNF-like ligand for DR3 and TR6\/DcR3 and functions as a T cell costimulator","volume":"16","author":"Migone","year":"2002","journal-title":"Immunity"},{"key":"2026082801031934500_izag172-B12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1136\/gutjnl-2024-332504","article-title":"Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD","volume":"74","author":"Bamias","year":"2025","journal-title":"Gut"},{"key":"2026082801031934500_izag172-B13","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa2314076","article-title":"Phase 2 trial of anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N Engl J Med"},{"key":"2026082801031934500_izag172-B14","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S2468-1253(25)00129-3","article-title":"Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial","volume":"10","author":"Danese","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026082801031934500_izag172-B15","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S2468-1253(26)00120-2","article-title":"Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial","volume":"11","author":"Reinisch","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026082801031934500_izag172-B16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S2468-1253(26)00119-6","article-title":"Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial","volume":"11","author":"Jairath","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026082801031934500_izag172-B17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S2468-1253(25)00071-8","article-title":"Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn\u2019s disease: a phase 2a induction trial","volume":"10","author":"Feagan","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026082801031934500_izag172-B18","author":"GlobeNewswire","year":"2025"},{"key":"2026082801031934500_izag172-B19","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3389\/fimmu.2019.00583","article-title":"TL1A (TNFSF15) and DR3 (TNFRSF25): a co-stimulatory system of cytokines with diverse functions in gut mucosal immunity","volume":"10","author":"Valatas","year":"2019","journal-title":"Front Immunol"},{"key":"2026082801031934500_izag172-B20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12026-013-8465-0","article-title":"Immunobiology of TNFSF15 and TNFRSF25","volume":"57","author":"Schreiber","year":"2013","journal-title":"Immunol Res"},{"key":"2026082801031934500_izag172-B21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1189\/jlb.3RI0315-095R","article-title":"The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator","volume":"98","author":"Richard","year":"2015","journal-title":"J Leukoc Biol"},{"key":"2026082801031934500_izag172-B22","doi-asserted-by":"publisher","first-page":"7636","DOI":"10.1021\/bi900031w","article-title":"Biochemical and structural characterization of the human TL1A ectodomain","volume":"48","author":"Zhan","year":"2009","journal-title":"Biochemistry"},{"key":"2026082801031934500_izag172-B23","doi-asserted-by":"publisher","first-page":"39251","DOI":"10.1074\/jbc.M305833200","article-title":"TL1A-induced NF-\u03baB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells","volume":"278","author":"Wen","year":"2003","journal-title":"J Biol Chem"},{"key":"2026082801031934500_izag172-B24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1600-065X.2011.01068.x","article-title":"TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation","volume":"244","author":"Meylan","year":"2011","journal-title":"Immunol Rev"},{"key":"2026082801031934500_izag172-B25","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1002\/eji.200839087","article-title":"Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells","volume":"39","author":"Shih","year":"2009","journal-title":"Eur J Immunol"},{"key":"2026082801031934500_izag172-B26","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.4049\/jimmunol.178.7.4033","article-title":"The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells","volume":"178","author":"Prehn","year":"2007","journal-title":"J Immunol"},{"key":"2026082801031934500_izag172-B27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/eji.201041950","article-title":"Death receptor 3 is essential for generating optimal protective CD4+ T-cell immunity against Salmonella","volume":"42","author":"Buchan","year":"2012","journal-title":"Eur J Immunol"},{"key":"2026082801031934500_izag172-B28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.immuni.2008.04.021","article-title":"The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases","volume":"29","author":"Meylan","year":"2008","journal-title":"Immunity"},{"key":"2026082801031934500_izag172-B29","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1002\/eji.201445213","article-title":"Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-2-dependent proliferation","volume":"45","author":"Ahn","year":"2015","journal-title":"Eur J Immunol"},{"key":"2026082801031934500_izag172-B30","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.4049\/jimmunol.171.9.4868","article-title":"Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease","volume":"171","author":"Bamias","year":"2003","journal-title":"J Immunol"},{"key":"2026082801031934500_izag172-B31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/ibd.21124","article-title":"TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn\u2019s disease","volume":"16","author":"Kamada","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"2026082801031934500_izag172-B32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.clim.2010.07.001","article-title":"High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis","volume":"137","author":"Bamias","year":"2010","journal-title":"Clin Immunol"},{"key":"2026082801031934500_izag172-B33","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1053\/j.gastro.2008.04.037","article-title":"TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation","volume":"135","author":"Takedatsu","year":"2008","journal-title":"Gastroenterology"},{"key":"2026082801031934500_izag172-B34","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1084\/jem.20071364","article-title":"TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease","volume":"205","author":"Pappu","year":"2008","journal-title":"J Exp Med"},{"key":"2026082801031934500_izag172-B35","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1084\/jem.20072528","article-title":"Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation","volume":"205","author":"Fang","year":"2008","journal-title":"J Exp Med"},{"key":"2026082801031934500_izag172-B36","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1053\/j.gastro.2025.03.035","article-title":"Tumor necrosis factor-like ligand 1A\/death receptor 3 signaling regulates the generation of pathogenic T helper 9 cells in experimental Crohn\u2019s disease","volume":"169","author":"Menghini","year":"2025","journal-title":"Gastroenterology"},{"key":"2026082801031934500_izag172-B37","doi-asserted-by":"publisher","first-page":"S-1257","DOI":"10.1016\/S0016-5085(26)03148-3","article-title":"Tu1460 TL1A drives TH1, TH2 and TH17 pathways in human lamina propria cells in IBD","volume":"170","author":"Llewellyn","year":"2026","journal-title":"Gastroenterology"},{"key":"2026082801031934500_izag172-B38","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/mi.2013.92","article-title":"TNF superfamily member TL1A elicits type 2 innate lymphoid cells at mucosal barriers","volume":"7","author":"Yu","year":"2014","journal-title":"Mucosal Immunol"},{"key":"2026082801031934500_izag172-B39","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/imr.13322","article-title":"Group 3 innate lymphoid cells: a trained Gutkeeper","volume":"323","author":"Serafini","year":"2024","journal-title":"Immunol Rev"},{"key":"2026082801031934500_izag172-B40","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/mi.2010.70","article-title":"Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia","volume":"4","author":"Taraban","year":"2011","journal-title":"Mucosal Immunol"},{"key":"2026082801031934500_izag172-B41","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1172\/JCI42933","article-title":"Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation","volume":"120","author":"Schreiber","year":"2010","journal-title":"J Clin Invest"},{"key":"2026082801031934500_izag172-B42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/mi.2010.67","article-title":"The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation","volume":"4","author":"Meylan","year":"2011","journal-title":"Mucosal Immunol"},{"key":"2026082801031934500_izag172-B43","doi-asserted-by":"publisher","first-page":"e16090","DOI":"10.1371\/journal.pone.0016090","article-title":"Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis","volume":"6","author":"Shih","year":"2011","journal-title":"PLoS One"},{"key":"2026082801031934500_izag172-B44","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1002\/ibd.21638","article-title":"SAMP1\/YitFc mouse strain: a spontaneous model of Crohn\u2019s disease-like ileitis","volume":"17","author":"Pizarro","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2026082801031934500_izag172-B45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ibd\/izy305","article-title":"Death-domain-receptor 3 deletion normalizes inflammatory gene expression and prevents ileitis in experimental Crohn\u2019s disease","volume":"25","author":"Butt\u00f3","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026082801031934500_izag172-B46","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/gut.2006.090456","article-title":"Wound healing and fibrosis in intestinal disease","volume":"56","author":"Rieder","year":"2007","journal-title":"Gut"},{"key":"2026082801031934500_izag172-B47","doi-asserted-by":"publisher","first-page":"5927064","DOI":"10.1155\/2021\/5927064","article-title":"Effect and mechanism of TL1A expression on epithelial-mesenchymal transition during chronic colitis-related intestinal fibrosis","volume":"2021","author":"Wenxiu","year":"2021","journal-title":"Mediators Inflamm"},{"key":"2026082801031934500_izag172-B48","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/s41385-018-0055-y","article-title":"Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome","volume":"11","author":"Jacob","year":"2018","journal-title":"Mucosal Immunol"},{"key":"2026082801031934500_izag172-B49","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11596-024-2875-1","article-title":"TL1A promotes fibrogenesis in colonic fibroblasts via the TGF-\u03b21\/Smad3 signaling pathway","volume":"44","author":"Song","year":"2024","journal-title":"Curr Med Sci"},{"key":"2026082801031934500_izag172-B50","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.4049\/jimmunol.2000665","article-title":"TL1A promotes lung tissue fibrosis and airway remodeling","volume":"205","author":"Herro","year":"2020","journal-title":"J Immunol"},{"key":"2026082801031934500_izag172-B51","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/ibd\/izab193","article-title":"Antitumor necrosis factor-like ligand 1A therapy targets tissue inflammation and fibrosis pathways and reduces gut pathobionts in ulcerative colitis","volume":"28","author":"Hassan-Zahraee","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026082801031934500_izag172-B52","doi-asserted-by":"publisher","first-page":"S-854","DOI":"10.1016\/S0016-5085(26)02287-0","article-title":"28 The anti-TL1A monoclonal antibody tulisokibart inhibits inflammatory and fibrosis pathways: results from a phase 2 ulcerative colitis study","volume":"170","author":"Rieder","year":"2026","journal-title":"Gastroenterology"},{"key":"2026082801031934500_izag172-B53","doi-asserted-by":"publisher","first-page":"S-1256","DOI":"10.1016\/S0016-5085(26)03146-X","article-title":"Tu1458 afimkibart normalizes serum protein networks toward healthy control levels in ulcerative colitis: results from the phase 2b tuscany-2 trial","volume":"170","author":"Chang","year":"2026","journal-title":"Gastroenterology"},{"key":"2026082801031934500_izag172-B54","author":"Merck","year":"2023"},{"key":"2026082801031934500_izag172-B55","doi-asserted-by":"publisher","first-page":"jjaf231.1018","DOI":"10.1093\/ecco-jcc\/jjaf231.1018","article-title":"P0837 Sustained symptomatic relief and disease clearance through 50 weeks of treatment with tulisokibart in participants with moderately to severely active ulcerative colitis in the phase 2 ARTEMIS-UC study","volume":"20","author":"Ma","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026082801031934500_izag172-B56","doi-asserted-by":"publisher","first-page":"S1046","DOI":"10.14309\/01.ajg.0000921046.65432.fc","article-title":"Long-term efficacy and safety of intravenous (IV) tulisokibart in patients with ulcerative colitis (UC): results from the open-label extension (OLE) period of the phase 2 ARTEMIS-UC study","volume":"119","author":"Ma","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026082801031934500_izag172-B57","author":"Merck","year":"2024"},{"key":"2026082801031934500_izag172-B58","author":"Merck","year":"2025"},{"key":"2026082801031934500_izag172-B59","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/bcp.14187","article-title":"First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects","volume":"86","author":"Banfield","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2026082801031934500_izag172-B60","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.cgh.2021.06.011","article-title":"Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: a phase 2a single-arm study","volume":"19","author":"Danese","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026082801031934500_izag172-B61","doi-asserted-by":"publisher","first-page":"jjaf231.347","DOI":"10.1093\/ecco-jcc\/jjaf231.347","article-title":"P0166 afimkibart downregulates Th17, myeloid, and fibrotic pathways in ulcerative colitis: serum proteomics from the phase 2b TUSCANY-2 trial","volume":"20","author":"Chang","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026082801031934500_izag172-B62","author":"Teva Pharmaceutical Industries","year":"2023"},{"key":"2026082801031934500_izag172-B63","author":"Sanofi, Teva Pharmaceutical Industries","year":"2026"},{"key":"2026082801031934500_izag172-B65","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1080\/19420862.2018.1440164","article-title":"An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease","volume":"10","author":"Clarke","year":"2018","journal-title":"MAbs"},{"key":"2026082801031934500_izag172-B64","doi-asserted-by":"publisher","first-page":"13733","DOI":"10.1074\/jbc.274.20.13733","article-title":"A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis","volume":"274","author":"Yu","year":"1999","journal-title":"J Biol Chem"},{"key":"2026082801031934500_izag172-B66","doi-asserted-by":"publisher","first-page":"jjaf231.228","DOI":"10.1093\/ecco-jcc\/jjaf231.228","article-title":"Afimkibart fully neutralizes TL1A activity, rendering DcR3-TL1A blockade biologically inconsequential","volume":"20","author":"Fuh","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026082801031934500_izag172-B67","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.3390\/ijms26115017","article-title":"TL1A as a target in inflammatory bowel disease: exploring mechanisms and therapeutic potential","volume":"26","author":"Tettoni","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026082801031934500_izag172-B68","doi-asserted-by":"publisher","first-page":"782788","DOI":"10.3389\/fimmu.2021.782788","article-title":"Immune complex formation is associated with loss of tolerance and an antibody response to both drug and target","volume":"12","author":"Kroenke","year":"2021","journal-title":"Front Immunol"},{"key":"2026082801031934500_izag172-B69","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S2468-1253(23)00193-0","article-title":"Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: a systematic review","volume":"8","author":"Pathiyil","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026082801031934500_izag172-B70","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S2468-1253(26)00007-5","article-title":"The evolving clinical trial landscape in the MENA region","volume":"11","author":"Quraishi","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026082801031934500_izag172-B71","author":"Merck Sharp & Dohme LLC","year":"2023"},{"key":"2026082801031934500_izag172-B72","author":"Merck Sharp & Dohme LLC","year":"2024"},{"key":"2026082801031934500_izag172-B73","author":"Hoffmann-La","year":"2024"},{"key":"2026082801031934500_izag172-B74","author":"Hoffmann-La","year":"2024"},{"key":"2026082801031934500_izag172-B75","author":"Hoffmann-La","year":"2025"},{"key":"2026082801031934500_izag172-B76","author":"Hoffmann-La","year":"2025"},{"key":"2026082801031934500_izag172-B77","author":"Sanofi","year":"2025"},{"key":"2026082801031934500_izag172-B78","author":"Sanofi","year":"2025"},{"key":"2026082801031934500_izag172-B79","author":"Sanofi","year":"2026"},{"key":"2026082801031934500_izag172-B80","author":"Sanofi","year":"2026"},{"key":"2026082801031934500_izag172-B81","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S2468-1253(25)00346-2","article-title":"Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease","volume":"11","author":"Shehab","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026082801031934500_izag172-B82","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1093\/hmg\/ddi379","article-title":"Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn\u2019s disease","volume":"14","author":"Yamazaki","year":"2005","journal-title":"Hum Mol Genet"},{"key":"2026082801031934500_izag172-B83","doi-asserted-by":"publisher","first-page":"e4719","DOI":"10.1371\/journal.pone.0004719","article-title":"IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein","volume":"4","author":"Michelsen","year":"2009","journal-title":"PLoS One"},{"key":"2026082801031934500_izag172-B84","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/hmg\/ddac269","article-title":"Trans-ancestry, Bayesian meta-analysis discovers 20 novel risk loci for inflammatory bowel disease in an African American, East Asian and European cohort","volume":"32","author":"Cordero","year":"2023","journal-title":"Hum Mol Genet"},{"key":"2026082801031934500_izag172-B85","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3109\/08916934.2014.932276","article-title":"Associations between TNFSF15 polymorphisms and susceptibility to ulcerative colitis and Crohn\u2019s disease: a meta-analysis","volume":"47","author":"Zhang","year":"2014","journal-title":"Autoimmunity"},{"key":"2026082801031934500_izag172-B86","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/ibd.20223","article-title":"TNFSF15 is an ethnic-specific IBD gene","volume":"13","author":"Picornell","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"2026082801031934500_izag172-B87","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/ng.3359","article-title":"Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations","volume":"47","author":"Liu","year":"2015","journal-title":"Nat Genet"},{"key":"2026082801031934500_izag172-B88","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41588-023-01384-0","article-title":"Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries","volume":"55","author":"Liu","year":"2023","journal-title":"Nat Genet"},{"key":"2026082801031934500_izag172-B89","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.crohns.2014.04.002","article-title":"TNFSF15 is an independent predictor for the development of Crohn\u2019s disease-related complications in Koreans","volume":"8","author":"Yang","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2026082801031934500_izag172-B90","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/bs.apha.2024.10.014","article-title":"TL1A: a model for a precision medicine approach in the treatment of Crohn\u2019s disease and ulcerative colitis","volume":"101","author":"Bilsborough","year":"2024","journal-title":"Adv Pharmacol"},{"key":"2026082801031934500_izag172-B91","doi-asserted-by":"publisher","first-page":"17562848231173331","DOI":"10.1177\/17562848231173331","article-title":"Precision medicine and drug optimization in adult inflammatory bowel disease patients","volume":"16","author":"Vieujean","year":"2023","journal-title":"Ther Adv Gastroenterol"},{"key":"2026082801031934500_izag172-B92","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1053\/j.gastro.2022.02.035","article-title":"Precision medicine in inflammatory bowel diseases: challenges and considerations for the path forward","volume":"162","author":"Ricciuto","year":"2022","journal-title":"Gastroenterology"},{"key":"2026082801031934500_izag172-B93","doi-asserted-by":"publisher","first-page":"S-1202","DOI":"10.1016\/S0016-5085(26)03032-5","article-title":"Mo1593 differential induction efficacy of anti-TL1A therapy in advanced-therapy experienced (ATE) vs advanced-therapy naive (ATN) patients with IBD: a systematic review and subgroup meta-analysis","volume":"103","author":"Sharma","year":"2026","journal-title":"Gastroenterology"},{"key":"2026082801031934500_izag172-B94","author":"DelveInsight","year":"2025"},{"key":"2026082801031934500_izag172-B95","doi-asserted-by":"publisher","first-page":"i1656","DOI":"10.1093\/ecco-jcc\/jjad212.1041","article-title":"P911 development and characterization of SPY002, a novel extended half-life monoclonal antibody drug candidate targeting TL1A for the treatment of IBD","volume":"18","author":"Zhu","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026082801031934500_izag172-B96","doi-asserted-by":"publisher","first-page":"jjaf231.1159","DOI":"10.1093\/ecco-jcc\/jjaf231.1159","article-title":"P0978 SKYLINE-UC: the first platform study in ulcerative colitis assessing efficacy and safety of three long-acting antibodies administered as single agents and in combinations","volume":"20","author":"Danese","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026082801031934500_izag172-B97","doi-asserted-by":"publisher","first-page":"S-1177","DOI":"10.1016\/S0016-5085(26)02977-X","article-title":"Mo1538 XMAB942, a potential best-in-class, long-acting anti-TL1A antibody for the treatment of inflammatory bowel disease: phase 1 final results","volume":"170","author":"Osterman","year":"2026","journal-title":"Gastroenterology"},{"key":"2026082801031934500_izag172-B98","doi-asserted-by":"publisher","first-page":"i2015","DOI":"10.1093\/ecco-jcc\/jjae190.1271","article-title":"P1097 Phase 1\/2 study to assess safety, tolerability, and efficacy of XmAb942 (anti-TL1A) in healthy participants and participants with ulcerative colitis","volume":"19","author":"Hung","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026082801031934500_izag172-B99","author":"Absci Corporation","year":"2024"},{"key":"2026082801031934500_izag172-B100","author":"AbbVie","year":"2024"},{"key":"2026082801031934500_izag172-B101","author":"Biocad JSC","year":"2025"},{"key":"2026082801031934500_izag172-B102","author":"Biocad JSC","year":"2025"},{"key":"2026082801031934500_izag172-B103","author":"Caldera Therapeutics","year":"2026"},{"key":"2026082801031934500_izag172-B104","doi-asserted-by":"publisher","first-page":"S-1259","DOI":"10.1016\/S0016-5085(26)03156-2","article-title":"Tu1468 discovery and characterization of XMAB412: a novel, high-affinity, anti-TL1A X ANTI-IL23 native-like bispecific antibody with extended half-life for the treatment of inflammatory bowel disease","volume":"170","author":"Faber","year":"2026","journal-title":"Gastroenterology"},{"key":"2026082801031934500_izag172-B105","doi-asserted-by":"publisher","first-page":"S-1260","DOI":"10.1016\/S0016-5085(26)03159-8","article-title":"Tu1471 development and preclinlical testing of a novel bispecific antibody targeting P40 and TL1A for enhanced IBD therapy","volume":"170","author":"Johnson","year":"2026","journal-title":"Gastroenterology"},{"key":"2026082801031934500_izag172-B106","doi-asserted-by":"publisher","first-page":"jjaf231.155","DOI":"10.1093\/ecco-jcc\/jjaf231.155","article-title":"DOP118 A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the p40xTL1A bispecific antibody PF-07261271 in healthy participants","volume":"20","author":"Sapone","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026082801031934500_izag172-B107","author":"Boehringer Ingelheim"},{"key":"2026082801031934500_izag172-B108","doi-asserted-by":"publisher","first-page":"vkaf283.2321","DOI":"10.1093\/jimmun\/vkaf283.2321","article-title":"Discovery and development of SIM0709, a novel bi-specific antibody targeting TL1A and IL23p19 for the treatment of IBD and beyond 4676","volume":"214","author":"Zhao","year":"2025","journal-title":"J Immunol"},{"key":"2026082801031934500_izag172-B109","doi-asserted-by":"publisher","first-page":"i1618","DOI":"10.1093\/ecco-jcc\/jjae190.1022","article-title":"P0848 engineering and development of a novel bispecific antibody targeting both TL1A and \u03b14\u03b27 for the treatment of IBD","volume":"19","author":"Ran","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026082801031934500_izag172-B110","doi-asserted-by":"publisher","first-page":"i2046","DOI":"10.1093\/ecco-jcc\/jjae190.1288","article-title":"P1114 engineering and development of a novel bispecific antibody targeting IL-23 and TL1A","volume":"19","author":"Huang","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026082801031934500_izag172-B111","doi-asserted-by":"publisher","first-page":"i1258","DOI":"10.1093\/ecco-jcc\/jjae190.0814","article-title":"P0640 Development and characterization of LQ080, a novel extended half-life bispecific TL1A\/IL-23 p19 single domain antibody for the treatment of IBD","volume":"19","author":"Wan","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026082801031934500_izag172-B112","author":"Earendil Labs","year":"2025"},{"key":"2026082801031934500_izag172-B113","doi-asserted-by":"publisher","first-page":"jjaf231.159","DOI":"10.1093\/ecco-jcc\/jjaf231.159","article-title":"DOP122 Preclinical evaluation of a TL1A\u2009\u00d7\u2009IL-23 bispecific antibody for immune-mediated inflammatory diseases","volume":"20","author":"Zhou","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026082801031934500_izag172-B114","doi-asserted-by":"publisher","first-page":"S-2079","DOI":"10.1016\/S0016-5085(25)05711-7","article-title":"177a: first-in-class oral TL1A nanobody and long-acting TL1A\/IL-23 bispecific nanobody: novel therapies for inflammatory bowel disease","volume":"169","author":"Wan","year":"2025","journal-title":"Gastroenterology"},{"key":"2026082801031934500_izag172-B115","author":"Shattuck Labs","year":"2025"},{"key":"2026082801031934500_izag172-B116","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026082801031934500_izag172-B117","doi-asserted-by":"publisher","first-page":"jjaf231.204","DOI":"10.1093\/ecco-jcc\/jjaf231.204","article-title":"P0023 Anti-TL1A and anti-IL-23 combination therapy is superior to its constituent monotherapies in mouse anti-CD40 colitis","volume":"20","author":"Siegel","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026082801031934500_izag172-B118","author":"Merck","year":"2026"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag172\/70823140\/izag172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag172\/70823140\/izag172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:43:38Z","timestamp":1787921018000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article\/doi\/10.1093\/ibd\/izag172\/8772152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":118,"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag172","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"izag172"}}